Mutations of the BCR-ABL kinase domain are a common mechanism of resistance to imatinib in chronic myeloid leukemia. We screened for mutations 171 patients failing imatinib therapy. Sixty-six mutations in 23 amino acids were identified in 62 (36%) patients not responding to imatinib. Phosphate-binding loop (P-loop) mutations were the most frequent (n ¼ 24; 36%). By multivariate analysis, factors associated with development of mutations were older age (P ¼ 0.026) prior interferon therapy (P ¼ 0.026), and accelerated phase or blast phase at time of imatinib failure (P ¼ 0.001). After a median follow-up of 38 months (range, 4-68 months) from the start of imatinib therapy, seven patients with non-P-loop and two with P-loop mutation died. By multivariate analysis, development of clonal evolution and higher percentage of peripheral blood basophils were associated with worse survival from the time of imatinib failure. Mutation status had no impact on survival. When survival was measured from the time therapy started, non-P-loop mutations together with duration of response and transformation at the time of failure to imatinib were associated with shorter survival. In conclusion, P-loop mutations were not associated with poor outcome, suggesting that the prognosis of patients who fail imatinib is multifactorial.
Introduction
Imatinib is standard therapy for patients with chronic myelogenous leukemia (CML) 1 with durable responses in most patients treated in chronic phase (CP). 2, 3 However, a subset of patients eventually develop resistance, particularly those treated in the advanced stages. 4, 5 Both BCR-ABL-dependent [4] [5] [6] [7] and -independent [8] [9] [10] mechanisms of resistance have been described. Point mutations of the Abl kinase domain appear to be the most common, occurring in 30-90% of patients who develop resistance. [4] [5] [6] [7] 11, 12 Mutations have been mapped to 435 different residues, 13 and biochemical and cellular assays have shown that different mutations have varying levels of resistance.
14 Some studies have suggested that patients with P-loop mutations have a particularly poor prognosis. 7, 12 The incidence, frequency and prognostic implications of different mutations may be influenced by multiple factors, including patient selection and therapeutic interventions. Herein we report on 171 patients with CML with an inadequate response to imatinib assessed for BCR-ABL kinase domain mutations. The objectives were to determine the clinical characteristics associated with development of mutations, and the relative frequency and prognostic significance of different mutations.
Patients and methods
From December 1999 to June 2004, 171 CML patients who failed imatinib were evaluated by DNA sequencing for mutations of the BCR-ABL kinase domain. Imatinib failure was defined as loss of a cytogenetic or complete hematologic response (CHR), or failure to achieve a CHR (CP patients only) or any hematologic response (for patients in accelerated -AP or blast phase -BP) after 3 months of therapy, or persistence of 100% Philadelphia chromosome (Ph)-positive metaphases after 6 months or X35% after 12 months. Patients with major cytogenetic response (MCyR) not achieving MMR (i.e., BCR-ABL/ABL ratio o0.05%) 2 and with increasing BCR-ABL transcript levels (at least 1Àlog) were considered to have inadequate response as this population was reported to have an increased risk of relapse and developing mutations. 2, 15 Patients were treated by IRB approved protocols and signed an informed consent as per institutional guidelines. The definitions of cytogenetic response, CP, AP and BP, and interferon (IFN) failure were as previously reported. [16] [17] [18] [19] All patients had pre-treatment cytogenetics, interphase fluorescence in situ hybridization and real-time PCR. Cytogenetics and PCR were repeated every 3-4 months for 1 year, and every 6 months thereafter. Patients were followed for survival at least every 3 months. Response criteria were as previously described. 20 Complete remission duration was considered from the time a complete cytogenetic response (CCyR) was first achieved to the time when the patient first lost CCyR (i.e., an increase to 40% Ph-positive). Survival was calculated from the time treatment began until death or last follow-up.
Mutation analysis
RNA was isolated from RBC-lysed total cells from peripheral blood or bone marrow by Trizol solubilization (Gibco-BRL, Gaithersburg, MD, USA) and cDNA synthesized by reverse transcriptase (Superscript II, Invitrogen, Carlson, CA, USA). The kinase domain of BCR-ABL was sequenced following nested PCR method. BCR-ABL was first amplified followed by two separate PCR reactions that cover amino acids 221-380 and codons 350-500 of the ABL kinase domain, respectively. After purification of PCR products through QIAquick columns (Qiagen, Valencia, CA, USA), standard dideoxy chain-termination DNA sequencing was performed using Big Dye chain terminator reagents on an automated ABI3700 analyzer and analyzed using Sequence Analysis software V3.3 and the SeqScape software V2 (ABI, Foster City, CA, USA). All mutations were confirmed by sequencing of forward and reverse strands.
TaqMan quantitative real-time RT-PCR
Levels of BCR-ABL fusion transcripts were quantitated in a multiplex real-time reverse transcription-PCR (RT-PCR) assay that simultaneously detects b2a2, b3a2 and e1a2 transcript types, as previously described. 2 Reverse transcription was performed on 1 mg of total RNA using random hexamers and Superscript II reverse transcriptase. The resulting cDNA was subjected to PCR to amplify BCR-ABL fusion transcripts on an ABI PRISM 7700 Sequence Detector (Perkin-Elmer/Applied Biosystems, Foster City, CA, USA) using primers and conditions described previously.
2 Absolute BCR-ABL and ABL transcript copy numbers were calculated separately by plotting threshold cycle (C T ) against a standard curves based on plasmid DNA at six dilution points, and the BCR-ABL/ABL ratio was calculated. The run-to-run variability of the assay established by repeat analysis of the same sample from RNA was 0.5-0.9 C T for BCR-ABL and 0.8-1.1 C T for ABL in the range of BCR-ABL/ABL ratios that triggered mutational analysis (i.e., 1-100%). Using absolute BCR-ABL and ABL transcript levels, the coefficient of variation for the BCR-ABL ratio over the relevant range monitored at regular intervals during the entire study was 21-44%. 2 
Statistical analysis
To evaluate the association between disease characteristics and outcome variables such as mutation status and survival, we applied a logistic regression model, Cox proportional hazards regression model, and Cox proportional hazards regression model with time-vary covariate. Descriptive statistics were analyzed, and univariate analyses using the w 2 test, Fisher's exact test, Wilcoxon rank sum test and Student's t-test were performed on categorical and continuous data. 21 The univariate and multivariate logistic regression models 22 were used to assess association between patient characteristics and mutation status. Estimates of survival curves were calculated according to Kaplan-Meier product-limit method. 23 Overall survival was defined in three different ways based on various starting points. They were from time of diagnosis of disease, or time of receiving imatinib or time of mutation to date of death or last follow-up. Clinical and biological characteristics were analyzed for their association with survival using standard Cox proportional hazards models. 24 However, the standard Cox regression model assumes that the effect of a covariate is constant throughout the course of the study. In our case, patients' mutation status changed after they received the treatment of imatinib. Therefore, both standard Cox proportional hazard regression models and Cox proportional hazards regression model with time-vary covariates were used to assess the relationship between mutation status and overall survival. Predictive variables with P-values of less than 0.10 for the univariate Cox proportional hazards model were included in a multivariate model. All computations were carried out on DELL PC using the Windows NT operating system in SAS (Cary, NC, USA) and S-plus 2000 (Cambridge, MS, USA).
Results

BCR-ABL kinase domain mutations
At the start of imatinib therapy, three (2%) of the 171 patients analyzed were in BP, 34 (20%) in AP, 66 (39%) in late-CP (i.e., 412 months from diagnosis) and 68 (40%) in early-CP (i.e., p12 months from the diagnosis). Ninety patients (53%) had failed IFN therapy. Median time on imatinib was 31 months (range, 2-63 months). Sixty-two (36%) of the 171 patients had 67 mutations that mapped to 23 amino acids, with the most frequent locating to the P-loop 13 in 24 patients (39% of patients with mutations). The single most common mutations were G250E (n ¼ 10), F317L (n ¼ 7), E355G/A (n ¼ 7) and M244V (n ¼ 6) ( Table 1 ). Four patients had two different mutations (detected simultaneously in three). Four patients were primarily resistant to imatinib and mutations were found in only one (G250E).
Mutations by disease stage at the time of imatinib therapy ( Table 2) Early-CP. Among 68 patients treated in early-CP, mutations were detected in 16 (24%). Although seven (44%) of 16 patients with mutations had achieved an MCyR, all 16 eventually developed resistance to imatinib within 13 months (range 1-12 months): 11 transformed to AP (n ¼ 7) or BP (n ¼ 4) (nine (56%) with clonal evolution -CE), four lost CHR but remained in CP, and one lost CCyR. In contrast, 29 of 52 (56%) without detectable mutations lost their cytogenetic or hematologic response after a median of 18 months (range, 2-48 months). Five of them transformed into AP and four into BP, and CE occurred in six (11%). Table 1 Mutations identified in 171 patients
a Four patients had two mutations. BP. Three patients (two myeloid, one lymphoid) were investigated. Only one (lymphoid BP) had a mutation (Q252H) detected within 4 months of start of therapy. This patient achieved a complete molecular remission 4 months after an allogeneic stem cell transplant performed in CCyR (increasing transcript levels). One of the other patients had a transient CHR and the other never achieved CHR.
Patient characteristics associated with mutations
We analyzed the patient characteristics associated with the presence of mutations (Tables 3a and b) . Patients with mutations were on average 9 years older than those without mutations (P ¼ 0.002), and the average time from diagnosis to treatment with imatinib was 13 months longer (P ¼ 0.037). Patients who had received prior IFN had a higher mutation rate (48%) than those without prior IFN (23%, P ¼ 0.001). Other features associated with increased frequency of mutations were disease transformation to AP or BP, development of CE, high-risk Sokal score at diagnosis and failure to achieve CCyR with imatinib. The association of CE with mutations was particularly strong for patients in early-CP compared to those in late-CP (56 vs 32% had CE, respectively; P ¼ 0.2). Mutations and CE were detected simultaneously in 56%, whereas CE antedated detection of mutation in 44%. Patients in CP received either standard-(400 mg, n ¼ 92) or high-dose (800 mg, n ¼ 35) imatinib, 25, 26 and mutations were less common among those treated with the high dose. In a multivariate analysis, variables independently associated with the presence of mutations were age (P ¼ 0.05), prior IFN therapy (P ¼ 0.026) and disease status at the time of assessment (CP vs AP, P ¼ 0.001; AP vs BP, P ¼ 0.092).
Survival analysis
It has been suggested that certain mutations may confer a worse survival from onset of therapy 27 (Corm et al., Blood 2004; 104: 82a, abstract), or from detection of mutation. 7 We thus analyzed the effect of mutations on survival from either of these time points.
Survival from time of assessment for mutation. After a median follow-up from diagnosis of 56 months (range, 4-240 months), nine of 62 (15%) patients with mutations and 12 of 109 without mutation (11%) died (P ¼ 0.63) (Figure 1 ). Among those with mutations, two of 23 (9%) with P-loop mutations and seven of 39 (18%) with other mutations died. In a univariate Cox proportional hazard regression model, baseline characteristics at the start of therapy associated with worse survival included Imatinib therapy and mutations in CML E Jabbour et al CE, stage (AP or BP) and a higher basophil or blast percentage in peripheral blood or bone marrow. Other characteristics associated with time to death included failure to achieve CCyR, the development of CE and transformation to AP or BP. In a multivariate analysis, only the presence of CE at the time of imatinib failure (P ¼ 0.029) and higher basophil percentage (0.008), and a trend for higher blast count (P ¼ 0.062) were associated with mortality. The presence of mutations or the specific mutation did not significantly affect the time to death (P ¼ 0.75).
Survival from start of therapy. Patients have been followed for a median of 38 months from the start of therapy with imatinib Imatinib therapy and mutations in CML E Jabbour et al (range, 4-68 months). In a univariate model, factors adversely affecting survival included the presence of CE or advanced stage disease at the start of therapy, a high blast or basophil percentage in peripheral blood or bone marrow, failure to achieve a CCyR to imatinib or a short remission duration, and transformation at the time of imatinib failure. Neither the presence of mutations nor the type of mutation was associated with survival when patients were grouped based on the presence or absence of mutations (i.e., considering it as a baseline covariate) (Figure 2a) . However, mutations appeared at different times from the start of imatinib; thus, the presence of mutations is a time-dependent covariate. When analyzed considering mutations as a time-dependent covariate, the development of mutations was associated with a significantly shorter survival (P ¼ 0.0002) (Figure 2b ). Non-P-loop mutations were particularly associated with a poor prognosis, whereas there was no significant difference in survival for patients with P-loop mutations (Figure 2c) . However, in a multivariate analysis, the disease stage at the start of treatment (AP or BP vs CP, P ¼ o0.0001) and shorter response duration (Po0.0001) were the only variables independently associated with an increased risk of death. The development or the type of mutations, as a time-dependent covariate, was not independently associated with survival (P ¼ 0.36).
The new tyrosine kinase inhibitors (TKI) nilotinib and dasatinib became available during the follow-up of this patient population. Because these agents have shown significant efficacy in the management of patients who failed imatinib and response to these or other agents may affect survival, we analyzed the treatment with nilotinib of dasatinib among the study patient population (Table 4) . Among patients with no mutations, 20 (18%) received these agents after a median of 13 months (range, 1-27 months) from imatinib failure. In contrast, 11 (46%) of those with P-loop mutations and 16 (42%) of patients with other mutations were treated with these agents after a median of 9 months (1-22 months) and 8 months (1-36 months), respectively, from imatinib failure (P ¼ NS). There was no difference in the number of patients receiving allogeneic stem cell transplant, but more patients with mutations received other investigational therapies.
Discussion
We present our experience with sequencing for mutations among 171 CML patients who failed imatinib therapy and identified mutations in 62 (36%). We report that P-loop mutations are not associated with an inferior outcome compared to other mutations or the absence of mutations among patients who failed imatinib. Mutations were identified in 23 different amino acids with P-loop mutations being the most common, in concordance with previous reports 7, 12 (Corm et al., Blood 2004; 104: 82a, abstract). We identified two mutations, F279L and V299L, which, to the best of our knowledge, have not been previously reported. Importantly, T315I was identified in only three patients, representing 4% of all mutations in 2% of all patients tested. Similarly, other studies found T315I in 0/19 12 and 2/27 (7%) patients with mutations (1% of all 144 investigated). 7 Other studies have found T315I in a significantly larger percentage of patients. 4, 28 The reason for this difference is not clear, and is possible that the relative frequency may increase as new agents that effectively treat other mutations (other than T315I) are used. Also, in view of the resistance of this mutation to imatinib and the newer TKI, the inclusion of these mutations among the non-P-loop mutation group in our series and others 7 may adversely bias the prognosis of this group of patients. However, two of the three patients with T315I in our series were still alive at the time of this analysis.
In a multivariate analysis, older age, prior IFN and advanced stage at the time of failure correlated with the occurrence of mutations. Factors associated with development of mutations were CE, prior 6-thioguanine exposure and low platelet count in one previous study, 29 and longer time from diagnosis to treatment and lack of MCyR in another. 7 Because of the different patient selection, these results cannot be compared. Still, some factors are common such as CE, prior therapy (IFN-a or 6-thiogunanine 29 ) and time from diagnosis. Few studies have investigated mutations among patients treated with imatinib as frontline therapy. 7, 12 Branford et al. 7 found no mutations among 24 such patients. We found mutations in 13 (23%) of 58 such patients. This is a population selected for their clinical resistance to imatinib and is therefore an over-representation compared to the total denominator of patients treated with imatinib in this setting. Older age was associated with only a trend for increased risk of mutations in one study. 29 In that series, age was treated as a categorical variable (p60 versus 460 years). We analyzed age as a continuous variable and found it highly significant with a 1 year increase in age increasing the odds of mutations by 6%.
P-loop mutations have been reported to confer a poor prognosis, with rapid transformation 12 and median survival of 4.5 months. 7 In our study, patients with P-loop mutations did not have a particularly poor prognosis compared to those with other or no mutations. One reason for the different outcome compared to others series 7, 12 (Corm et al., Blood 2004; 104: 82a, abstract) is the patient selection. We analyzed for mutations a subset of patients still in cytogenetic remission, although they had failed to achieve MMR and had increasing transcript levels. Branford et al. 7 included only patients who had received imatinib for at least 6 months or had developed resistance before 6 months. Soverini et al. 12 investigated only patients in CP who failed to achieve an MMR after 12 months of therapy. In our series, 11 patients did not meet the criteria used by Branford et al. 7 and 16 patients did not meet the criteria of Soverini et al. 12 None of these 27 patients had mutations and their inclusion in our analysis indeed favorably affects the prognosis of the group with no mutations. We repeated the analysis excluding these patients and, as expected, the conclusions were identical (data not shown). Another factor that may significantly affect the outcome after a mutation is identified is the treatment the patient receives. Several strategies, particularly the new TKI, may overcome resistance to imatinib (Jabbour et al., Blood 2005; 106: 318a, abstract) and many of our patients received these approaches, which may have favorably influenced their survival. There was no difference in the type of therapy used for patients with P-loop and other mutations (e.g., 46% with P-loop and 42% with other mutations received therapy with nilotinib or dasatinib), although more patients with any mutation received these agents compared to those without mutations (18%). Stem cell transplant has also been reported to be a valuable option for patients with mutations, 30 and there was no difference in the frequency of transplantation among all groups. In contrast, Soverini et al. 12 reported one patient treated with allogeneic transplant, 15 with conventional chemotherapy, usually hydroxyurea, and others continued imatinib. That report 12 and the one by Branford et al. 7 antedate the wide availability of new TKI, which is likely a major reason for the different results. A more contemporary analysis (Hochhaus et al., Blood, 2005; 106: 316a, abstract) did not confirm a survival disadvantage for patients with P-loop mutations, even after censoring at the time of TKI therapy. That report suggested that withdrawal of imatinib may improve the prognosis. Finally, in other series, the presence of mutations is analyzed as if it was a baseline variable. This is particularly important when survival is measured from time of start of therapy that usually antecedes the detection of mutations. Although occasionally, in patients, mutations may be present at baseline, 29 most will develop during therapy. No instances of mutations early CP before start of imatinib have been reported. One patient reported by RocheLestienne et al. 31 had CE and could be considered in AP. We analyzed mutations as a time-dependent covariate, and this influences the effect on survival, mostly owing to the poor survival of patients with non-P-loop mutations. Thus, the impact of mutations on survival is multifactorial. In addition, the extent of resistance to imatinib and other TKI of different mutations within the P-loop and other areas of the kinase domain vary greatly. 32 Thus, the P-loop is a heterogenous group of mutations, which make our results not surprising. It is currently more important to analyze the impact of mutations, both pre-clinical and clinical, individually rather than as families. (25) 13 (54) 20 (53) 0.009 a Includes tipifarnib alone or in combination with imatinib, lonafarnib alone or in combination with imatinib, homoharringtonine, decitabine or combination chemotherapy.
